Study of nausea and vomiting from T-DXd in breast cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study looks at nausea and vomiting caused by a breast cancer treatment called T-DXd. It aims to understand these side effects and help manage them better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with breast cancer.
- You are getting your first full dose of T-DXd therapy.
- You are well enough to be up and about (ECOG score 2 or lower).
- You are not taking certain medications for nausea, vomiting, or pain that could affect the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether the anti-nausea combination NEPA (netupitant and palonosetron) can prevent nausea and vomiting caused by the targeted therapy T-DXd in people with advanced HER2-positive or HER2-low breast cancer. It may help you if you are about to start T-DXd for the first time and want to manage treatment side effects.
This trial tests a combination of two drugs, T-DXd (a targeted therapy) and an immunotherapy, before surgery for people with early-stage breast cancer that has low levels of HER2 and is hormone receptor positive. The goal is to see if this treatment can shrink the tumor or eliminate cancer cells before surgery.
This study looks at people with advanced breast cancer who will receive a drug called T-DXd. Researchers want to understand the side effects of this treatment by analyzing blood samples.
This study looks at how well Trastuzumab Deruxtecan (T-DXd) works in Chinese women with breast cancer that has spread. It is for people whose cancer is either HER2-positive or HER2-low and who have already had some treatment.
This study looks at how safe and effective the drug T-DXd (trastuzumab deruxtecan) is for Chinese patients with a specific type of lung cancer that has a HER2 mutation. It helps understand if this treatment works well in real-world settings.
This trial is studying a drug called T-DXd (trastuzumab deruxtecan) for Chinese women with advanced breast cancer that has a certain protein (HER2) either in high or low amounts. It aims to see how well the drug works in real-world settings.
Hear when a new Breast Cancer Patients Treated With T-DXd trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.